SecBot SecBot
Biotech Drug Report Generated Nov 14, 2026

FT839

FATE·FATE THERAPEUTICS INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
IND cleared / preclinical
Time to market
Early preclinical/IND-stage; if clinical trials begin soon, a potential approval is likely 5+ years away, assuming successful Phase 1/2/3 development.
Why 3/10
No hard dated binary catalyst is scheduled within the next 12 months (the IND was already cleared in July 2026 and the next milestone is clinical-trial enrollment, which has no confirmed date). FT839 is a preclinical/IND-stage program and not the lead asset at Fate Therapeutics, so its share-price impact is limited. The impactScore defaults toward the lower end of the scale.
Actionable Insight NEUTRAL

The next catalyst for FT839 is the initiation of its Phase 1/2 basket study and first patient dosed, which was projected for H2 2026 but has not yet been announced as of November 13, 2026. Watch for a press release on trial initiation; a positive outcome would de-risk the dual-target mechanism but remains a development-stage milestone with no efficacy data for at least 12-18 months. FATE's share price is far more dependent on FT819's Phase 2 RECLAIM-LN lupus nephritis readout than on FT839 progress.

Price Chart

Loading chart...

Executive Summary

FT839 is a preclinical, next-generation, off-the-shelf CAR T-cell therapy from Fate Therapeutics (FATE). It is a first-of-kind dual CD19/CD38-targeting, 13-point-genetically-edited iPSC-derived product candidate designed to treat autoimmune diseases and hematological malignancies without conditioning chemotherapy. The FDA cleared its IND application in July 2026, and preclinical data were presented at ACR Convergence 2026 (November 10, 2026). Enrollment in a Phase 1/2 basket study was expected to begin in H2 2026, but no clinical-trial initiation or first-patient-dosed announcement has been made as of mid-November 2026. FT839 is an early-stage program well behind the company's lead asset, FT819 (Phase 2 in lupus nephritis), and has no hard binary catalyst in the next 12 months, limiting its near-term share-price impact for FATE.

How It Works

FT839 is a CAR T-cell therapy made from engineered stem cells (iPSCs) that can be mass-produced and stored, then given to any patient without needing to modify the patient's own cells (off-the-shelf). It is engineered with two targeting molecules (dual CAR) that recognize two proteins on disease-causing immune cells: CD19 and CD38. By hitting both targets, it is designed to eliminate a broader range of harmful immune cells than single-target CAR Ts. It also carries a suite of 13 genetic edits intended to let it work without the harsh chemotherapy normally used to prepare the body for cell therapy.

Trial Status

FT839 received FDA IND clearance in July 2026 for autoimmune diseases. Preclinical data were presented at ACR Convergence 2026 (November 2026). Enrollment in a Phase 1/2 basket study for autoimmune diseases and hematological malignancies was projected to begin H2 2026, but no trial initiation or patient dosing has been announced as of November 13, 2026.

The Two-Sided Case

▲ Bull Case4
First-of-kind dual CD19/CD38-targeting CAR T could address a broader range of autoimmune conditions than single-target CAR Ts, differentiating FT839 from competitors.
Engineered to work without conditioning chemotherapy, which could dramatically expand the addressable patient population if confirmed in humans.
Built on Fate's proprietary iPSC platform, enabling an off-the-shelf (allogeneic) product with potentially lower cost and greater manufacturing scalability than personalized CAR Ts.
Analyst consensus on FATE implies 327% upside (mean target $5.72 vs $1.34 current price), with 11 of 18 analysts rating the stock Buy or Strong Buy.
▼ Bear Case5
FT839 is still at the preclinical/IND stage with no patients dosed; the dual-target mechanism has not been clinically validated and may face unexpected safety or efficacy hurdles.
FATE is a micro-cap stock trading near $1.28 with a ~52-week range of $0.95-$3.23; any clinical setback could disproportionately pressure the stock.
Fate Therapeutics carries significant cash-burn risk as a clinical-stage biotech with no approved products; FT839's development competes for resources with the lead program FT819.
The dual CD19/CD38 approach may carry overlapping toxicity risks seen with other CD19 CAR Ts (cytokine release syndrome, neurotoxicity) compounded by dual targeting.
Other companies (e.g., CABennett, Kyverna) are also developing CAR T therapies for autoimmune diseases, creating a competitive landscape FT839 must differentiate against.

Upcoming Catalysts

  • Initiation of Phase 1/2 basket study and first patient dosed (projected H2 2026, no announcement yet)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

FATE THERAPEUTICS INC 424B5 FATE ·Originating report

Sources · 7

Hover a chip for the title
1 nasdaq.com2 marketscreener.com3 bioworld.com4 finanznachrichten.de5 markets.financialcontent.com6 markets.businessinsider.com7 msn.com